



Pharmacy and Therapeutics Advisory Forum

WellCare Health Plan

Zoom Meeting ID: 923 7977 8929

Password: 602343

<https://centene.zoom.us/j/92379778929?>

Join by phone

+1 646 931 3860 or +1 669 444 9171

August 24, 2020

8:30 AM – 10:00 AM

Agenda

- I. Call to Order – WellCare Introductions & Announcements
- II. Old Business – Updates from May 18th P&T Meeting
- III. New Business
 - a. Drug Class Reviews

Drug Class
Vaccines
Toxoids
Passive Immunizing Agents (Immunoglobulins, Synagis)
Antineoplastic Agents
Antihistamines
Decongestants
Cough/Cold
Antiasthmatics
Misc. Respiratory
Ophthalmic
Otic
Mouth & throat
Anorectal
Dermatological



Pharmacy and Therapeutics Advisory Forum

I. New Drugs to Market

a. Drug Reviews

Brand name (generic)	FDA Approval Date	Market/Launch Date
AVSOLA™ (infliximab-axxq) NEW BIOSIMILAR	12/6/2019	5/27/2020
Bafiertam™ (monomethyl fumarate) New Formulation	4/30/2020	8/3/2020
Barhemsys® (amisulpride) New Molecular Entity	2/26/2020	8/4/2020
Blenrep (belantamab mafodotin-blmf) New Biologic	8/5/2020	8/7/2020
BONSITY™ (teriparatide) NEW FORMULATION	10/4/2019	3/25/2020
Breztri Aerosphere™ (budesonide/ glycopyrrolate/ formoterol fumarate) New Combination	7/23/2020	7/31/2020
DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) NEW FORMULATION	5/1/2020	5/4/2020
DOJOLVI™ (triheptanoin) NEW MOLECULAR ENTITY	6/30/2020	7/10/2020
Durysta™ (bimatoprost implant) NEW FORMULATION	3/4/2020	5/13/2020
EVRYSDI™ (risdiplam) New Molecular Entity	8/7/2020	8/10/2020
FENSOLVI® (leuprolide acetate) NEW FORMULATION	5/1/2020	6/25/2020
FERRIPROX® (deferiprone) NEW FORMULATION	5/19/2020	7/6/2020

Pharmacy and Therapeutics Advisory Forum

Brand name (generic)	FDA Approval Date	Market/Launch Date
FINTEPLA™ (fenfluramine) NEW FORMULATION	6/25/2020	6/29/2020
Inqovi® (decitabine/ cedazuridine) New Molecular Entity	7/7/2020	8/10/2020
Jelmyto™ (mitomycin) NEW FORMULATION	4/15/2020	5/13/2020
KYNMOBI™ (apomorphine) NEW FORMULATION	5/21/2020	6/9/2020
LYUMJEV™ (insulin lispro-aabc) NEW BIOLOGIC	6/15/2020	6/18/2020
MONJUVI® (tafasitamab-cxix) New Biologic	7/31/2020	8/4/2020
MYCAPSSA™ (octreotide) NEW FORMULATION	6/26/2020	7/10/2020
NEXLIZET™ (bempedoic acid/ ezetimibe) NEW COMBINATION	2/26/2020	5/22/2020
ORIAHNN® (elagolix/ estradiol/ norethindrone acetate and elagolix) NEW COMBINATION	5/29/2020	6/3/2020
ORTIKOS™ (budesonide extended release) NEW FORMULATION	6/13/2019	7/16/2020
PHESGO™ (pertuzumab/ trastuzumab/ hyaluronidase-zzxf) NEW COMBINATION	6/29/2020	7/1/2020
PHEXXI™ (L-lactic acid/ citric acid/ potassium bitartrate) NEW COMBINATION	5/22/2020	6/5/2020
Qinlock™ (riporetinib) NEW MOLECULAR ENTITY	5/15/2020	5/19/2020



Pharmacy and Therapeutics Advisory Forum

Brand name (generic)	FDA Approval Date	Market/Launch Date
RETEVMO™ (selpercatinib) NEW MOLECULAR ENTITY	5/8/2020	5/11/2020
RUKOBIA™ (fostemsavir) NEW MOLECULAR ENTITY	7/2/2020	7/7/2020
TABRECTA™ (capmatinib) NEW MOLECULAR ENTITY	5/6/2020	5/8/2020
Tecartus™ (brexucabtagene autoleucel) BLA-Hospital Administered	7/24/2020	7/31/2020
TIVICAY PD® (dolutegravir) NEW FORMULATION	6/12/2020	6/16/2020
TWIRLA® (ethinyl estradiol/ levonorgestrel) NEW FORMULATION	2/14/2020	6/29/2020
UPLIZNA™ (inebilizumab-cdon) NEW BIOLOGIC	6/11/2020	6/22/2020
Upneeq (oxymetazoline) New Formulation	7/8/2020	8/11/2020
ZEPOSIA® (ozanimod) NEW MOLECULAR ENTITY	3/25/2020	5/25/2020
ZEPZELCA™ (lurbinectedin) NEW MOLECULAR ENTITY	6/15/2020	6/23/2020
ZILXI™ (minocycline) NEW FORMULATION	5/28/2020	6/9/2020

b. Speaker Drug Reviews (*Requests to present must be submitted prior to meeting)

II. Adjournment

a. Future Meeting Dates

11/23/20